Medable
Clinical trial technology platform combining decentralized trial execution and electronic clinical outcome assessment with an agentic AI layer added in 2026. Agent Studio is a no code agent builder the company describes as the first agentic AI platform purpose built for clinical development, letting sponsor teams configure agents for protocol development, trial planning, and data workflows, with human in the loop validation and integration across life sciences systems. Shipped agents include TMF Agent for trial master file document management, announced January 2026, and a Digital Data Flow Agent that converts trial protocols into machine readable data. The underlying platform is reported deployed in nearly 400 trials across 70 countries and 120 languages, serving more than one million patients, and was named a Leader in eCOA by Everest Group. Founded 2014; CEO and cofounder Dr Michelle Longmire.
Capability Axes
The established product is a decentralized trial and eCOA platform, and the agentic layer arrived in 2026. Agent Studio and the shipped TMF and Digital Data Flow agents are substantive rather than cosmetic, and the no code agent builder is a real capability. Graded C because a buyer purchasing Medable today is primarily purchasing trial execution infrastructure onto which agents are configured, not a model.
Human in the loop validation is stated as a design principle of Agent Studio, alongside conformance to life sciences standard operating procedures, regulatory and validation requirements, and benchmarking against trusted sources. That regulated context imposes real audit discipline. Held back from A because escalation thresholds and failure handling for individual agents are not documented publicly.
Platform scale is substantial and consistently reported: nearly 400 trials across 70 countries and 120 languages serving more than one million patients, with independent recognition as a Leader in eCOA by Everest Group. Held back from A because that evidence supports the trial platform rather than the 2026 agentic layer, for which no outcome data was retrieved. Agent performance and platform track record are separate claims.
No public pricing. Contact the vendor. Enterprise agreements with pharmaceutical sponsors and CROs; no published rate card.
Precisely bounded: sponsor side clinical development, spanning decentralized and hybrid trial execution, eCOA, eConsent, and trial document operations. No clinical care claims are made, which is appropriate to the buyer.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Sponsor and CRO agreements, scoped per study or program | — | — | Vendor Published |
Enterprise agreements with pharmaceutical sponsors and CROs, typically scoped per study or per program. No rate card published.